Financhill
Back

Blueprint Medicines Stock Price Chart

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and BPMC is experiencing slight buying pressure.

Blueprint Medicines Price Chart Indicators

Moving Averages Level Buy or Sell
8-day SMA: 92.88 Sell
20-day SMA: 94.44 Sell
50-day SMA: 92.37 Sell
200-day SMA: 96.72 Sell
8-day EMA: 92.45 Sell
20-day EMA: 93.6 Sell
50-day EMA: 93.36 Sell
200-day EMA: 91.74 Sell

Blueprint Medicines Technical Analysis Indicators

Chart Indicators Level Buy or Sell
MACD (12, 26): -0.52 Sell
Relative Strength Index (14 RSI): 42.23 Sell
Chaikin Money Flow: 540770 -
Bollinger Bands Level Buy or Sell
Bollinger Bands (25): (91.73 - 96.57) Sell
Bollinger Bands (100): (87.46 - 96.54) Sell

Blueprint Medicines Technical Analysis

Technical Analysis: Buy or Sell?
8-day SMA:
20-day SMA:
50-day SMA:
200-day SMA:
8-day EMA:
20-day EMA:
50-day EMA:
200-day EMA:
MACD (12, 26):
Relative Strength Index (14 RSI):
Bollinger Bands (25):
Bollinger Bands (100):

Technical Analysis for Blueprint Medicines Stock

Is Blueprint Medicines Stock a Buy?

BPMC Technical Analysis vs Fundamental Analysis

Sell
40
Blueprint Medicines (BPMC) is a Sell

Is Blueprint Medicines a Buy or a Sell?

Blueprint Medicines Stock Info

Market Cap:
5.7B
Price in USD:
90.19
Share Volume:
1.2M

Blueprint Medicines 52-Week Range

52-Week High:
121.90
52-Week Low:
72.24
Sell
40
Blueprint Medicines (BPMC) is a Sell

Blueprint Medicines Share Price Forecast

Is Blueprint Medicines Stock a Buy?

  • Blueprint Medicines share price is 90.19 while BPMC 8-day exponential moving average is 92.45, which is a Sell signal.
  • The stock price of BPMC is 90.19 while Blueprint Medicines 20-day EMA is 93.60, which makes it a Sell.
  • Blueprint Medicines 50-day exponential moving average is 93.36 while BPMC share price is 90.19, making it a Sell technically.
  • BPMC stock price is 90.19 and Blueprint Medicines 200-day simple moving average is 91.74, creating a Sell signal.

Fundamental Analysis of Blueprint Medicines

Is Blueprint Medicines a good investment?

  • Analysts estimate an earnings increase this quarter of $0.73 per share, a decrease next quarter of $0.00 per share, an increase this year of $7.18 per share, and an increase next year of $0.57 per share.

Technical Analysis of Blueprint Medicines

Should I short Blueprint Medicines stock?

* Blueprint Medicines stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.